Konstantin Kazankov

Prognose og behandling af nonalkoholisk fedtleversygdom og steatohepatitis

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperReviewResearch

Non-alcoholic fatty liver disease (NAFLD) and steatohepatitis (NASH) are among the most common liver diseases. NAFLD with pure steatosis is considered benign. NASH, however, may progress to liver cirrhosis with risk of liver cancer. Therefore, it is important to search for treatment modalities for NASH. Because obesity and insulin resistance are risk factors for NASH, weight loss and exercise are considered mandatory, although limited data are in support. Presently, we focus on the prognosis of NAFLD and NASH and on pharmaceutical treatment, especially in the form of vitamin E and pioglitazone.
Original languageDanish
JournalUgeskrift for Laeger
Volume174
Issue8
Pages (from-to)488-490
Number of pages3
ISSN0041-5782
Publication statusPublished - 2012

See relations at Aarhus University Citationformats

ID: 44450984